Imraldi

Adalimumab, the active ingredient in Imraldi, is a TNF‑alpha inhibitor presented as a 40 mg solution for injection for subcutaneous use. It treats autoimmune inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa and non‑infectious uveitis in adult patients.

GNH USA supplies Imraldi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imraldi is a biologic DMARD that modulates the TNF‑alpha pathway in several chronic inflammatory diseases. - Rheumatoid arthritis: reduces joint pain, swelling and structural damage. - Psoriatic arthritis: improves skin lesions and joint symptoms. - Ankylosing spondylitis: alleviates spinal inflammation and stiffness. - Plaque psoriasis: clears plaques and reduces scaling. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve clinical remission and mucosal healing.

Adalimumab may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site reactions: redness, swelling or pain at the injection site. - Upper respiratory infections: nasopharyngitis, sinusitis. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Serious infections: tuberculosis, bacterial, fungal or viral infections. - Malignancies: lymphoma, skin cancers. - Hepatic injury: elevated liver enzymes or hepatitis. - Demyelinating disorders: multiple sclerosis‑like symptoms. - Heart failure exacerbation: worsening of existing cardiac failure.

Before initiating therapy, patients should be evaluated for infection risk and baseline laboratory values. - Screen for latent TB: perform tuberculin skin test or interferon‑gamma release assay. - Monitor for infections: report fever, cough, or unexplained malaise promptly. - Assess liver function: periodic testing of ALT, AST and bilirubin. - Evaluate cardiac status: avoid in uncontrolled heart failure. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other immunomodulatory agents and vaccines.

Major Interactions (Avoid): - Live vaccines: may cause disseminated infection; avoid concurrent administration. - Antifungal agents (e.g., azoles) used for systemic infections: may increase infection risk.

Moderate Interactions (Monitor Closely): - Other biologics (e.g., abatacept, rituximab): increased immunosuppression. - Immunosuppressants (e.g., methotrexate, azathioprine): monitor for additive infection risk. - Cytochrome P450 substrates: may require dose adjustment due to cytokine‑mediated enzyme changes.